Fill 1 Return To RT

View Table of Contents

Biosimilars in Retinal Disease Management

Table of Contents

Biosimilars in Retinal Disease Management

Peter K. Kaiser, MD David Brown, MD Diana V. Do, MD

What is a Biosimilar?

Phase 3 Clinical Trial Data for Ranibizumab-Nuna

Assessing the Totality of the Evidence: How regulatory bodies review reference medications versus biosimilars.
Assessing the Totality of the Evidence: How regulatory bodies review reference medications versus biosimilars. image
Assessing the Totality of the Evidence: How regulatory bodies review reference medications versus biosimilars. image

Sponsored by Biogen

January/February 2023 Supplement | Biosimilars in Retinal Disease Management

Assessing the Totality of the Evidence: How regulatory bodies review reference medications versus biosimilars.

Share:

Biosimilars in Retinal Disease Management

Table of Contents

Biosimilars in Retinal Disease Management

Peter K. Kaiser, MD David Brown, MD Diana V. Do, MD

What is a Biosimilar?

Phase 3 Clinical Trial Data for Ranibizumab-Nuna

Assessing the Totality of the Evidence: How regulatory bodies review reference medications versus biosimilars.